4
|
Kingsbury SR, Tharmanathan P, Keding A, Watt FE, Scott DL, Roddy E, Birrell F, Arden NK, Bowes M, Arundel C, Watson M, Ronaldson SJ, Hewitt C, Doherty M, Moots RJ, O'Neill TW, Green M, Patel G, Garrood T, Edwards CJ, Walmsley PJ, Sheeran T, Torgerson DJ, Conaghan PG. Pain Reduction With Oral Methotrexate in Knee Osteoarthritis : A Randomized, Placebo-Controlled Clinical Trial. Ann Intern Med 2024. [PMID: 39074374 DOI: 10.7326/m24-0303] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 07/31/2024] Open
Abstract
BACKGROUND Treatments for osteoarthritis (OA) are limited. Previous small studies suggest that the antirheumatic drug methotrexate may be a potential treatment for OA pain. OBJECTIVE To assess symptomatic benefits of methotrexate in knee OA (KOA). DESIGN A multicenter, randomized, double-blind, placebo-controlled trial done between 13 June 2014 and 13 October 2017. (ISRCTN77854383; EudraCT: 2013-001689-41). SETTING 15 secondary care musculoskeletal clinics in the United Kingdom. PARTICIPANTS A total of 207 participants with symptomatic, radiographic KOA and knee pain (severity ≥4 out of 10) on most days in the past 3 months with inadequate response to current medication were approached for inclusion. INTERVENTION Participants were randomly assigned 1:1 to oral methotrexate once weekly (6-week escalation 10 to 25 mg) or matched placebo over 12 months and continued usual analgesia. MEASUREMENTS The primary end point was average knee pain (numerical rating scale [NRS] 0 to 10) at 6 months, with 12-month follow-up to assess longer-term response. Secondary end points included knee stiffness and function outcomes and adverse events (AEs). RESULTS A total of 155 participants (64% women; mean age, 60.9 years; 50% Kellgren-Lawrence grade 3 to 4) were randomly assigned to methotrexate (n = 77) or placebo (n = 78). Follow-up was 86% (n = 134; methotrexate: 66, placebo: 68) at 6 months. Mean knee pain decreased from 6.4 (SD, 1.80) at baseline to 5.1 (SD, 2.32) at 6 months in the methotrexate group and from 6.8 (SD, 1.62) to 6.2 (SD, 2.30) in the placebo group. The primary intention-to-treat analysis showed a statistically significant pain reduction of 0.79 NRS points in favor of methotrexate (95% CI, 0.08 to 1.51; P = 0.030). There were also statistically significant treatment group differences in favor of methotrexate at 6 months for Western Ontario and McMaster Universities Osteoarthritis Index stiffness (0.60 points [CI, 0.01 to 1.18]; P = 0.045) and function (5.01 points [CI, 1.29 to 8.74]; P = 0.008). Treatment adherence analysis supported a dose-response effect. Four unrelated serious AEs were reported (methotrexate: 2, placebo: 2). LIMITATION Not permitting oral methotrexate to be changed to subcutaneous delivery for intolerance. CONCLUSION Oral methotrexate added to usual medications demonstrated statistically significant reduction in KOA pain, stiffness, and function at 6 months. PRIMARY FUNDING SOURCE Versus Arthritis.
Collapse
Affiliation(s)
- Sarah R Kingsbury
- Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, and National Institute for Health and Care Research (NIHR) Leeds Biomedical Research Centre, Leeds, United Kingdom (S.R.K., P.G.C.)
| | - Puvan Tharmanathan
- York Trials Unit, Department of Health Sciences, Faculty of Science, University of York, Heslington, York, United Kingdom (P.T., A.K., C.A., M.W., S.J.R., C.H., D.J.T.)
| | - Ada Keding
- York Trials Unit, Department of Health Sciences, Faculty of Science, University of York, Heslington, York, United Kingdom (P.T., A.K., C.A., M.W., S.J.R., C.H., D.J.T.)
| | - Fiona E Watt
- Centre for Inflammatory Disease, Department of Immunology and Inflammation, Hammersmith Campus, Imperial College London, and Centre for Osteoarthritis Pathogenesis Versus Arthritis, Kennedy Institute of Rheumatology, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, and Department of Rheumatology, Oxford University Hospitals NHS Foundation Trust, and Centre for Sport, Exercise and Osteoarthritis Research Versus Arthritis, Oxford, United Kingdom (F.E.W.)
| | - David L Scott
- King's College London, London, United Kingdom (D.L.S.)
| | - Edward Roddy
- Primary Care Centre Versus Arthritis, Keele University, and Haywood Academic Rheumatology Centre, Midlands Partnership University NHS Foundation Trust, Keele, United Kingdom (E.R.)
| | - Fraser Birrell
- Medical Research Council-Versus Arthritis Centre for Integrated Research into Musculoskeletal Ageing, Newcastle University, and Northumbria Healthcare NHS Foundation Trust, Newcastle upon Tyne, United Kingdom (F.B.)
| | - Nigel K Arden
- Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, and Centre for Sport, Exercise and Osteoarthritis Research Versus Arthritis, University of Oxford, Oxford, United Kingdom (N.K.A.)
| | - Mike Bowes
- Imorphics, Manchester, United Kingdom (M.B.)
| | - Catherine Arundel
- York Trials Unit, Department of Health Sciences, Faculty of Science, University of York, Heslington, York, United Kingdom (P.T., A.K., C.A., M.W., S.J.R., C.H., D.J.T.)
| | - Michelle Watson
- York Trials Unit, Department of Health Sciences, Faculty of Science, University of York, Heslington, York, United Kingdom (P.T., A.K., C.A., M.W., S.J.R., C.H., D.J.T.)
| | - Sarah J Ronaldson
- York Trials Unit, Department of Health Sciences, Faculty of Science, University of York, Heslington, York, United Kingdom (P.T., A.K., C.A., M.W., S.J.R., C.H., D.J.T.)
| | - Catherine Hewitt
- York Trials Unit, Department of Health Sciences, Faculty of Science, University of York, Heslington, York, United Kingdom (P.T., A.K., C.A., M.W., S.J.R., C.H., D.J.T.)
| | - Michael Doherty
- Academic Rheumatology and Pain Centre Versus Arthritis, University of Nottingham, Nottingham, United Kingdom (M.D.)
| | - Robert J Moots
- Faculty of Heath Social Care and Medicine, Edge Hill University, Ormskirk, and Department of Rheumatology, Aintree University Hospital, Liverpool, United Kingdom (R.J.M.)
| | - Terence W O'Neill
- Centre for Epidemiology Versus Arthritis, Division of Musculoskeletal and Dermatological Sciences, Manchester Academic Health Science Centre, University of Manchester, and NIHR Manchester Biomedical Research Centre, Manchester University NHS Foundation Trust, Manchester, United Kingdom (T.W.O.)
| | - Michael Green
- Harrogate and District NHS Foundation Trust, Harrogate, and York Teaching Hospital NHS Foundation Trust, York, United Kingdom (M.G.)
| | - Gulam Patel
- Rheumatology Department, Ashford and St. Peter's Hospital NHS Trust, Chertsey, United Kingdom (G.P.)
| | - Toby Garrood
- Department of Rheumatology, Guy's and St. Thomas' NHS Trust, London, United Kingdom (T.G.)
| | - Christopher J Edwards
- NIHR Southampton Clinical Research Facility, University Hospital Southampton NHS Foundation Trust, Southampton, United Kingdom (C.J.E.)
| | - Phil J Walmsley
- Department of Orthopaedics, Victoria Hospital Kirkcaldy and School of Medicine, St. Andrews University, Fife and Fife NHS Trust, Kirkcaldy, United Kingdom (P.J.W.)
| | - Tom Sheeran
- Department of Rheumatology, Royal Wolverhampton Hospitals NHS Trust, Wolverhampton, United Kingdom (T.S.)
| | - David J Torgerson
- York Trials Unit, Department of Health Sciences, Faculty of Science, University of York, Heslington, York, United Kingdom (P.T., A.K., C.A., M.W., S.J.R., C.H., D.J.T.)
| | - Philip G Conaghan
- Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, and National Institute for Health and Care Research (NIHR) Leeds Biomedical Research Centre, Leeds, United Kingdom (S.R.K., P.G.C.)
| |
Collapse
|
6
|
Jin Y, Guo C, Abbasian M, Abbasifard M, Abbott JH, Abdullahi A, Abedi A, Abidi H, Abolhassani H, Abu-Gharbieh E, Aburuz S, Abu-Zaid A, Addo IY, Adegboye OA, Adepoju AV, Adikusuma W, Adnani QES, Aghamiri S, Ahmad D, Ahmed A, Aithala JP, Akhlaghi S, Akkala S, Alalwan TA, Albashtawy M, Alemi H, Alhalaiqa FAN, Ali EA, Almustanyir S, Al-Raddadi RM, Alvis-Zakzuk NJ, Al-Worafi YM, Alzahrani H, Alzoubi KH, Amiri S, Amu H, Amzat J, Anderson DB, Anil A, Antony B, Arabloo J, Areda D, Artaman A, Artamonov AA, Aryal KK, Asghari-Jafarabadi M, Ashraf T, Athari SS, Atinafu BT, Atout MMW, Azadnajafabad S, Azhdari Tehrani H, Azzam AY, Badawi A, Baghcheghi N, Bai R, Baigi V, Banach M, Banakar M, Banik B, Bardhan M, Bärnighausen TW, Barqawi HJ, Barrow A, Bashiri A, Batra K, Bayani M, Bayileyegn NS, Begde A, Beyene KA, Bhagavathula AS, Bhardwaj P, Bhatti GK, Bhatti JS, Bhatti R, Bijani A, Bitra VR, Brazo-Sayavera J, Buchbinder R, Burkart K, Bustanji Y, Butt MH, Cámera LA, Carvalho F, Chattu VK, Chaurasia A, Chen G, Chen H, Chen L, Christensen SWM, Chu DT, Chukwu IS, Comachio J, Cruz-Martins N, Cuschieri S, Dadana S, Dadras O, Dai X, Dai Z, Das S, Dashti M, Delgado-Enciso I, Demisse B, Denova-Gutiérrez E, Desye B, Dewan SMR, Dhingra S, Diress M, Do TC, Do THP, Doan KDK, Dutta S, Dziedzic AM, Edinur HA, Ekholuenetale M, Elhadi M, Eskandarieh S, Esposito F, Fagbamigbe AF, Farokh P, Fatehizadeh A, Feizkhah A, Fekadu G, Ferreira N, Fetensa G, Fischer F, Foroutan B, Foroutan Koudehi M, Franklin RC, Fukumoto T, Gandhi AP, Ganesan B, Gau SY, Gautam RK, Gebre AK, Gebregergis MW, Ghaderi Yazdi B, Gholami A, Gill TK, Goleij P, Gomes-Neto M, Goyal A, Graham SM, Guan B, Gupta B, Gupta IR, Gupta S, Gupta VB, Gupta VK, Habibzadeh F, Hailu WB, Hajibeygi R, Halwani R, Haro JM, Hartvigsen J, Hasaballah AI, Haubold J, Hebert JJ, Hegazy MI, Heidari G, Heidari M, Hezam K, Hiraike Y, Hosseinzadeh H, Hosseinzadeh M, Hoveidaei AH, Hsu CJ, Huda MN, Huynh HH, Hwang BF, Ibitoye SE, Ikiroma AI, Ilic IM, Ilic MD, Iranmehr A, Islam SMS, Ismail NE, Iso H, Iwagami M, Iyasu AN, Jacob L, Jafarzadeh A, Jahankhani K, Jain N, Jairoun AA, Janakiraman B, Jayarajah U, Jayaram S, Jeganathan J, Jokar M, Jonas JB, Joo T, Joseph N, Joshua CE, Kabito GG, Kamal VK, Kandel H, Kantar RS, Karami J, Karaye IM, Karimi Behnagh A, Kaur N, Kazemi F, Kedir S, Khadembashiri MM, Khadembashiri MA, Khader YS, Khajuria H, Khan MJ, Khan MAB, Khan Suheb MZ, Khatatbeh H, Khatatbeh MM, Khateri S, Khayat Kashani HR, Khonji MS, Khubchandani J, Kian S, Kisa A, Kitila AT, Kolahi AA, Koohestani HR, Korzh O, Kostev K, Kotnis AL, Koyanagi A, Krishan K, Kuddus M, Kumar N, Kurniasari MD, Ladan MA, Lahariya C, Laksono T, Lallukka T, Landires I, Lasrado S, Lawal BK, Le TTT, Le TDT, Lee M, Lee WC, Lee YH, Lerango TL, Lim D, Lim SS, Lucchetti G, Ma ZF, Maghazachi AA, Maghbouli N, Malakan Rad E, Malhotra A, Malik AA, Mansournia MA, Mantovani LG, Manu E, Mathangasinghe Y, Mazzotti A, McPhail SM, Mengist B, Mesregah MK, Mestrovic T, Miller TR, Minh LHN, Mirahmadi Eraghi M, Mirrakhimov EM, Misganaw A, Mohamadian H, Mohamadkhani A, Mohamed NS, Mohammadi E, Mohammadi S, Mohammed M, Mojiri-Forushani H, Mokdad AH, Momenzadeh K, Momtazmanesh S, Monasta L, Montazeri F, Moradi Y, Morrison SD, Mostafavi E, Mousavi P, Mousavi SE, Mulita A, Murillo-Zamora E, Mustafa G, Muthu S, Naik GR, Naimzada MD, Nakhostin Ansari N, Narasimha Swamy S, Nargus S, Nascimento PR, Naseri A, Natto ZS, Naveed M, Nayak BP, Nazri-Panjaki A, Negaresh M, Negash H, Nejadghaderi SA, Nguyen DH, Nguyen HTH, Nguyen HQ, Nguyen PT, Nguyen VT, Niazi RK, Ofakunrin AO, Okati-Aliabad H, Okonji OC, Olatubi MI, Ommati MM, Ordak M, Owolabi MO, P A M, Padubidri JR, Pan F, Pantazopoulos I, Park S, Patel J, Patil S, Pawar S, Pedersini P, Peprah P, Perna S, Petcu IR, Petermann-Rocha FE, Pham HT, Pigeolet M, Prates EJS, Rahim F, Rahimi Z, Rahimi-Dehgolan S, Rahimi-Movaghar V, Rahman MHU, Rahmati M, Ramasamy SK, Ramasubramani P, Rapaka D, Rashedi S, Rashedi V, Rashidi MM, Rasouli-Saravani A, Rawaf S, Reddy MMRK, Redwan EMM, Rezaei N, Rezaei N, Rezaei N, Rezaei Z, Riad A, Roever L, Roshanzamir S, Roy P, de Andrade Ruela G, Saad AM, Saddik B, Sadeghian F, Saeed U, Safary A, Saghazadeh A, Sagoe D, Sharif-Askari FS, Sharif-Askari NS, Sahebkar A, Sakshaug JW, Salami AA, Saleh MA, Salehi S, Samadzadeh S, Samodra YL, Samuel VP, Santos DB, Santric-Milicevic MM, Saqib MAN, Saravanan A, Sawyer S, Schaarschmidt BM, Senapati S, Sethi Y, Seylani A, Shafaat A, Shafie M, Shahabi S, Shahbandi A, Shahrokhi S, Shaikh MA, Shamim MA, Shamshirgaran MA, Sharfaei S, Sharifan A, Sharifi A, Sharma R, Sharma S, Shashamo BB, Shi L, Shigematsu M, Shiri R, Shivarov V, Siddig EE, Sinaei E, Singh A, Singh JA, Singh P, Singh S, Singla S, Siraj MS, Skryabina AA, Solanki R, Solomon Y, Starodubova AV, Swain CK, Talic S, Tat NY, Temsah MH, Terefa DR, Tesler R, Thapar R, Tharwat S, Thayakaran R, Ticoalu JHV, Tovani-Palone MR, Tusa BS, Ty SS, Udoakang AJ, Vahabi SM, Valizadeh R, Van den Eynde J, Varthya SB, Vasankari TJ, Venketasubramanian N, Villafañe JH, Vlassov V, Vo AT, Vu LG, Wang YP, Wiangkham T, Wickramasinghe ND, Winkler AS, Wu AM, Yadollahpour A, Yahya G, Yonemoto N, You Y, Younis MZ, Zakham F, Zangiabadian M, Zarrintan A, Zhong C, Zhou H, Zhu Z, Zielińska M, Zikarg YT, Zitoun OA, Zoladl M, Tam LS, Wu D. Global pattern, trend, and cross-country inequality of early musculoskeletal disorders from 1990 to 2019, with projection from 2020 to 2050. MED 2024:S2666-6340(24)00179-X. [PMID: 38834074 DOI: 10.1016/j.medj.2024.04.009] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/02/2023] [Revised: 03/18/2024] [Accepted: 04/24/2024] [Indexed: 06/06/2024]
Abstract
BACKGROUND This study aims to estimate the burden, trends, forecasts, and disparities of early musculoskeletal (MSK) disorders among individuals ages 15 to 39 years. METHODS The global prevalence, years lived with disabilities (YLDs), disability-adjusted life years (DALYs), projection, and inequality were estimated for early MSK diseases, including rheumatoid arthritis (RA), osteoarthritis (OA), low back pain (LBP), neck pain (NP), gout, and other MSK diseases (OMSKDs). FINDINGS More adolescents and young adults were expected to develop MSK disorders by 2050. Across five age groups, the rates of prevalence, YLDs, and DALYs for RA, NP, LBP, gout, and OMSKDs sharply increased from ages 15-19 to 35-39; however, these were negligible for OA before age 30 but increased notably at ages 30-34, rising at least 6-fold by 35-39. The disease burden of gout, LBP, and OA attributable to high BMI and gout attributable to kidney dysfunction increased, while the contribution of smoking to LBP and RA and occupational ergonomic factors to LBP decreased. Between 1990 and 2019, the slope index of inequality increased for six MSK disorders, and the relative concentration index increased for gout, NP, OA, and OMSKDs but decreased for LBP and RA. CONCLUSIONS Multilevel interventions should be initiated to prevent disease burden related to RA, NP, LBP, gout, and OMSKDs among individuals ages 15-19 and to OA among individuals ages 30-34 to tightly control high BMI and kidney dysfunction. FUNDING The Global Burden of Disease study is funded by the Bill and Melinda Gates Foundation. The project is funded by the Scientific Research Fund of Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital (2022QN38).
Collapse
|